Literature DB >> 22549387

Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension.

S Günther1, X Jaïs, S Maitre, A Bérezné, P Dorfmüller, A Seferian, L Savale, O Mercier, E Fadel, O Sitbon, L Mouthon, G Simonneau, M Humbert, D Montani.   

Abstract

OBJECTIVE: Pulmonary venoocclusive disease (PVOD) is an uncommon form of pulmonary hypertension (PH) characterized by obstruction of small pulmonary veins. Pulmonary venous involvement has been reported in pathologic assessment of patients with systemic sclerosis (SSc) presenting with precapillary PH. High-resolution computed tomography (HRCT) of the chest is a noninvasive diagnostic tool used to screen for PVOD. No HRCT data are available on SSc patients with precapillary PH. We undertook this study to evaluate the frequency and effect on prognosis of HRCT signs of PVOD in SSc patients with precapillary PH.
METHODS: We reviewed chest HRCT data from 26 SSc patients with precapillary PH and 28 SSc patients without pulmonary arterial hypertension (PAH) or interstitial lung disease (ILD).
RESULTS: The radiographic triad of HRCT signs of PVOD (lymph node enlargement [57.7% versus 3.6%], centrilobular ground-glass opacities [46.2% versus 10.7%], and septal lines [88.5% versus 7.1%]) was significantly more frequent in SSc patients with precapillary PH than in SSc patients without PAH or ILD (all P < 0.005). Indeed, 61.5% of SSc patients with precapillary PH had ≥ 2 of these signs. Cardiomegaly (P < 0.0001), pulmonary artery enlargement (P < 0.0001), and pericardial effusion (P < 0.0005) were also significantly more frequent in SSc patients with precapillary PH. Pulmonary venous involvement was histologically confirmed in 2 patients with radiographic signs of PVOD. The presence of ≥ 2 radiographic signs of PVOD was associated with the occurrence of pulmonary edema after initiation of PAH-specific therapy (in 8 of 16 patients) and with more rapid progression from diagnosis of PH to death.
CONCLUSION: HRCT signs of PVOD are frequently observed in SSc patients with precapillary PH, correlated with histologic assessment, and were associated with a high risk of pulmonary edema.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2012        PMID: 22549387     DOI: 10.1002/art.34501

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  24 in total

Review 1.  Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment.

Authors:  Elisabetta Zanatta; Pamela Polito; Giulia Famoso; Maddalena Larosa; Elena De Zorzi; Elena Scarpieri; Franco Cozzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-22

2.  An official American Thoracic Society Statement: pulmonary hypertension phenotypes.

Authors:  Raed A Dweik; Sharon Rounds; Serpil C Erzurum; Stephen Archer; Karen Fagan; Paul M Hassoun; Nicholas S Hill; Marc Humbert; Steven M Kawut; Michael Krowka; Evangelos Michelakis; Nicholas W Morrell; Kurt Stenmark; Rubin M Tuder; John Newman
Journal:  Am J Respir Crit Care Med       Date:  2014-02-01       Impact factor: 21.405

3.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

Review 4.  Early detection of pulmonary arterial hypertension.

Authors:  Edmund M T Lau; Marc Humbert; David S Celermajer
Journal:  Nat Rev Cardiol       Date:  2014-11-25       Impact factor: 32.419

5.  Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.

Authors:  Rennie L Rhee; Nicole B Gabler; Amy Praestgaard; Peter A Merkel; Steven M Kawut
Journal:  Arthritis Rheumatol       Date:  2015-09       Impact factor: 10.995

Review 6.  Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension.

Authors:  J G Coghlan; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

Review 7.  Pulmonary veno-occlusive disease: a probably underdiagnosed cause of pulmonary hypertension in systemic sclerosis.

Authors:  Ana Catarina Duarte; Ana Cordeiro; Maria José Loureiro; Filipa Ferreira
Journal:  Clin Rheumatol       Date:  2020-01-22       Impact factor: 2.980

Review 8.  Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).

Authors:  Vincent Sobanski; David Launay; Eric Hachulla; Marc Humbert
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

Review 9.  Relevant issues in the pathology and pathobiology of pulmonary hypertension.

Authors:  Rubin M Tuder; Stephen L Archer; Peter Dorfmüller; Serpil C Erzurum; Christophe Guignabert; Evangelos Michelakis; Marlene Rabinovitch; Ralph Schermuly; Kurt R Stenmark; Nicholas W Morrell
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

Review 10.  Computed tomography appearances of the lung parenchyma in pulmonary hypertension.

Authors:  Robert W Foley; Nirav Kaneria; Rob V MacKenzie Ross; Jay Suntharalingam; Benjamin J Hudson; Jonathan Cl Rodrigues; Graham Robinson
Journal:  Br J Radiol       Date:  2020-09-11       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.